Advances in carvedilol to cirrhotic portal hypertension
CHENG Ran
XU Xiao-yuan
Abstract：Non-selective β-blockers (propranolol, nadolol) have been clinically used in patients with cirrhotic portal hypertension and can reduce portosystemic pressure gradient. Carvedilol, a new non-selective β-blocker, has dual effects of β-and α-blockers. In this paper, the pharmacological mechanism of carvedilol, the hemodynamic response rate between carvedilol and propranolol, primary and secondary prevention of esophagogastric variceal bleeding, remission effect on portal hypertensive gastropathy and suitability in patients with ascites are summarized for providing a better guidance to clinic practice.
Keywords：portal hypertensionnon-selective β-blockerscarvedilolpropranolo
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 184-188 )